Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prospective observational study of subcutaneous abatacept safety and effectiveness in rheumatoid arthritis
NL-OMON39013Phase 4Recruiting
- Sponsor
- Jan van Breemen Institute
- Start
- Sep 2013
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of abatacept in rheumatoid arthritis (RA), sponsored by Jan van Breemen Institute. Primary endpoints: Disease activity change from baseline, Radiological progression and 2 more. Started Sep 2013; status: recruiting.
02
Drugs
abatacept
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NL-OMON39013.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON39013.